MedTrace Logo

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

NCT03139981 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-05-10

No results posted yet for this study

Summary

This is a dose escalation study to test the safety, tolerability and preliminary efficacy of ASN002 in people with moderate to severe atopic dermatitis (AD).

Conditions

  • Dermatitis, Atopic
  • Dermatitis Eczema
  • Dermatitis, Eczematous

Interventions

DRUG

ASN002

Daily dose of ASN002 for 28 days

DRUG

Placebo Oral Tablet

Placebo for ASN002 for 28 days

Sponsors & Collaborators

  • Asana BioSciences

    lead INDUSTRY

Principal Investigators

  • David Zammit, Ph.D. · Asana BioSciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-12
Primary Completion
2017-11-05
Completion
2017-12-05
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03139981 on ClinicalTrials.gov